Drug intelligence / Profile preview

CBI-7261

Development stage: Preclinical
Lead developer: Liminal BioSciences
Modality: Small Molecules

Overview

CBI-7261 is a novel, potent, and selective small molecule antagonist of the Oxoeicosanoid Receptor 1 (OXER1), developed by Liminal BioSciences. OXER1 is a G protein-coupled receptor (GPCR) that is highly selective for 5-oxo-eicosatetraenoic acid (5-oxo-ETE), a potent human eosinophil chemo-attractant. By blocking OXER1, CBI-7261 aims to inhibit the recruitment and activation of eosinophils, which play a central role in the pathophysiology of allergic, inflammatory, and proliferative diseases. The therapeutic focus for this compound includes eosinophil-driven conditions such as asthma, atopic dermatitis, and eosinophilic esophagitis. As of early 2024, the program is in the preclinical development stage.

Targets

OXER1 (Oxoeicosanoid receptor 1)

Beyond the preview

Go deeper on CBI-7261.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBI-7261.

Explore the full profile